

ILTE STUDY NEWSLETTER – May 2007

Dear ILTE investigators, please enclosed find a resume' of latest ILTE initiatives.

40% target accrual reached.

Thanks to the work of many of you, the first 200 patients (or 40% of the target) have now been registered. This is the first result of this global collaborative effort and I want to thank all the centers that already sent their registration files.

I encourage the other ILTE investigators to follow quickly with their data.

I recognize that some of you have decided to participate only recently and therefore your contribution will arrive later. In any case please consider that on October 1st the new files for prospective follow up (I year) will be distributed to you and that on that date the database will be locked. Therefore registration files received after September 30, 2007 from centers already part of ILTE, will not be accepted.

Deceased patients

An important issue related to patients that died. These patients are important especially if they died because of CML unrelated causes. Therefore please consider (**and register**) all consecutive patients at your center who meet the eligibility criteria (started imatinib 1999-2004, CCyR after 2 years of imatinib). The registration of only a subset of eligible patients would introduce a selection bias that we must avoid.

In the case of eligible patients who later died of CML, they will be considered for ILTE until they lost CCyR.

ILTE dinners

Two dinners have been organized for ILTE investigators who will attend ASCO and/or EHA. If you have not yet done it, please reply to Miriam Puttini (Miriam.Puttini@unimib.it) by May 24th .

With best regards,

Carlo Gambacorti-Passerini MD, Lucia Tornaghi RN, ILTE Coordination Office

Maria Grazia Valsecchi PhD, Laura Antolini PhD, ILTE Statistical Unit